Sophiris Bio Inc (SPHS) Expected to Post Earnings of -$0.13 Per Share
Equities research analysts expect Sophiris Bio Inc (NASDAQ:SPHS) to post earnings of ($0.13) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Sophiris Bio’s earnings, with estimates ranging from ($0.17) to ($0.10). Sophiris Bio posted earnings of ($0.09) per share in the same quarter last year, which would indicate a negative year over year growth rate of 44.4%. The business is expected to report its next earnings report on Thursday, August 9th.
According to Zacks, analysts expect that Sophiris Bio will report full year earnings of ($0.51) per share for the current fiscal year, with EPS estimates ranging from ($0.69) to ($0.39). For the next year, analysts expect that the firm will report earnings of ($0.53) per share, with EPS estimates ranging from ($0.65) to ($0.40). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that cover Sophiris Bio.
Sophiris Bio (NASDAQ:SPHS) last released its quarterly earnings data on Monday, May 14th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.02.
Shares of Sophiris Bio stock traded down $0.06 on Friday, hitting $3.09. The stock had a trading volume of 124,085 shares, compared to its average volume of 905,853. Sophiris Bio has a twelve month low of $1.80 and a twelve month high of $4.05. The company has a quick ratio of 5.90, a current ratio of 5.90 and a debt-to-equity ratio of 1.30.
An institutional investor recently bought a new position in Sophiris Bio stock. Millennium Management LLC bought a new stake in shares of Sophiris Bio Inc (NASDAQ:SPHS) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 199,705 shares of the biopharmaceutical company’s stock, valued at approximately $453,000. Millennium Management LLC owned 0.66% of Sophiris Bio as of its most recent filing with the Securities and Exchange Commission. 5.55% of the stock is owned by institutional investors.
Sophiris Bio Company Profile
Sophiris Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer.
Recommended Story: What do investors mean by earnings per share?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sophiris Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio and related companies with MarketBeat.com's FREE daily email newsletter.